Comparison of the effects of Jinghua Weikang capsules and bismuth potassium citrate in anti-Helicobacter pylori infection
10.3760/cma.j.issn.1008-6706.2020.02.012
- VernacularTitle: 荆花胃康胶丸与铋剂在抗幽门螺杆菌中的效果比较
- Author:
Dongya LIU
1
;
Nan JIANG
1
;
Yi ZHAO
1
;
Ruixiang GONG
1
;
Dazheng HAN
1
Author Information
1. Department of Gastroenterology, the First Affiliated Hospital of He'nan University, Kaifeng, He'nan 475000, China
- Publication Type:Journal Article
- Keywords:
Helicobacter pylori;
Peptic ulcer;
Drug therapy, combination;
Jinghua Weikang capsule;
Comparative effectiveness research
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(2):179-182
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the effects of Jinghua Weikang capsule and bismuth potassium citrate in the treatment of Helicobacter pylori(Hp) infection.
Methods:From July 2016 to April 2018, 124 patients who were diagnosed as Hp positive by gastrointestinal urease test and 13C breath test at the First Affiliated Hospital of He'nan University were randomly divided into group A(63 cases) and group B(61 cases) according to the digital table.Group A received bismuth potassium citrate + standard triple therapy, treatment for 14 days.Group B was given Jinghua Weikang capsule+ standard triple therapy, treatment for 14 days.One month after treatment, the treatment effect of the two regimens was recorded.
Results:The total effective rates of group A and group B after one course of treatment were 88.89%(56/63) and 93.44%(57/61), respectively, the difference was no statistically significant between the two groups(χ2=0.795, P=0.373). The Hp eradication rates of group A and group B were 84.13%(53/63) and 95.08%(58/61), respectively, the difference was statistically significant(χ2=3.963, P=0.047). The proportions of patients with improved symptoms within 7 days in group A and group B were 68.25%(43/63) and 83.61%(51/61), respectively, the difference was statistically significant(χ2=3.983, P=0.046). The incidences of adverse reactions in group A and group B were 14.29%(9/63) and 3.28%(2/61), respectively, the difference was statistically significant(χ2=4.645, P=0.031).
Conclusion:Compared with bismuth potassium citrate, Jinghua Weikang capsule has similar clinical effect after one course of treatment, higher Hp eradication rate, lower incidence of adverse reactions, faster symptom improvement, and the satisfaction and compliance of patients are higher.
